Clinical correlates, heritability, and genetic linkage of circulating CD40 ligand in the Framingham Offspring Study - 08/08/11
, Izabella Lipinska, PhD b, Martin G. Larson, ScD c, Josée Dupuis, PhD d, Jane E. Freedman, MD a, b, Naomi M. Hamburg, MD a, b, Joseph M. Massaro, PhD d, e, Jian Rong, MS c, Patrice Sutherland, BS c, Joseph A. Vita, MD a, b, Ramachandran S. Vasan, MD a, c, e, Emelia J. Benjamin, MD, ScM a, b, c, eRiassunto |
Background |
The CD40 receptor and its ligand (CD40L) are known to modulate both inflammation and thrombosis—2 processes important for the development and clinical expression of atherosclerosis. Circulating soluble CD40L (sCD40L) concentration predicts cardiovascular risk in selected patient samples. The purpose of this study was to determine the predictors of sCD40L in a large, community-based sample.
Methods |
We determined both serum and plasma sCD40L concentration in 3,259 participants (54% women) from the Framingham Offspring Study.
Results |
In multivariable models, advancing age was the only consistent (inverse) correlate of both serum and plasma sCD40L concentration. Overall, the variability explained by clinical covariates was very low for both measurements of sCD40L; with values of only 1.4% and 2.7% for serum and plasma, respectively. We observed that genetic factors accounted for a modest (12% serum; 14% plasma) amount of the adjusted variability in sCD40L.
Conclusions |
Circulating sCD40L concentration was poorly associated with known cardiovascular disease (CVD) risk factors and was modestly heritable. Determining if either serum or plasma sCD40L are predictive of CVD risk in the community will require longitudinal follow-up.
Il testo completo di questo articolo è disponibile in PDF.Mappa
| This work was supported by the National Heart, Lung, and Blood Institute's Framingham Heart Study (contract no. N01-HC-25195). This work was supported by the National Institutes of Health's Framingham Heart Study N01-HC-25195, HL076784, and HL64753 (E.J.B.), NS17950 and HL04334 (R.S.V.), and AG027081 and HL68758 (J.F.K.). |
Vol 156 - N° 5
P. 1003 - Novembre 2008 Ritorno al numero
Articolo precedente
- Platelet reactivity and response to aspirin in subjects with the metabolic syndrome
- Muthiah Vaduganathan, Carlos L. Alviar, Mehmet E. Arikan, Armando Tellez, Sadishar Guthikonda, Timothy DeLao, Juan F. Granada, Neal S. Kleiman, Christie M. Ballantyne, Eli I. Lev
- Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb ischemia
- Satoaki Matoba, Tetsuya Tatsumi, Toyoaki Murohara, Tsutomu Imaizumi, Yousuke Katsuda, Masaaki Ito, Yoshihiko Saito, Shiro Uemura, Hiroshi Suzuki, Shinya Fukumoto, Yasutaka Yamamoto, Rie Onodera, Satoshi Teramukai, Masanori Fukushima, Hiroaki Matsubara, TACT Follow-up Study Investigators k
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?